Group 1 - The core index, the CESHKB, increased by 1.74% to 9852.81 points with a trading volume of 14.774 billion [1] - The CESHKB index has risen by 20.92% in the past month, 69.27% in the past three months, and 116.13% year-to-date [1] - The index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten weighted stocks in the CESHKB index include: - CanSino Biologics (13.72%) - Innovent Biologics (9.48%) - 3SBio (8.99%) - WuXi Biologics (8.61%) - BeiGene (8.53%) - WuXi AppTec (6.93%) - Kintor Pharmaceutical (4.94%) - Zai Lab (4.28%) - Nuo Therapeutics (4.1%) - Genscript Biotech (3.78%) [1] - The CESHKB index is entirely composed of stocks listed on the Hong Kong Stock Exchange, with 100% allocation [2] - The index's holdings are exclusively in the healthcare sector, with 100% allocation to the pharmaceutical and healthcare industry [2]

Group 1 - The core index, the CESHKB, increased by 2.22% to 9684.5 points with a trading volume of 19.513 billion [1] - The CESHKB index has risen by 21.28% over the past month, 67.37% over the past three months, and 111.44% year-to-date [1] - The index is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, and a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB index include: - CanSino Biologics (13.85%) - Innovent Biologics (9.49%) - WuXi Biologics (8.72%) - 3SBio (8.71%) - BeiGene (8.39%) - WuXi AppTec (7.03%) - Kintor Pharmaceutical (5.02%) - Zai Lab (4.33%) - Nuo Therapeutics (3.91%) - Kingstar Biotech (3.8%) [1] - The CESHKB index is fully composed of companies listed on the Hong Kong Stock Exchange, with 100% of its holdings in the healthcare sector [2]

Core Insights - The CESHKB index has shown significant growth, with a year-to-date increase of 102.54% [1] - The index reflects the overall performance of biotechnology companies listed in Hong Kong [1] Group 1: Index Performance - The CESHKB index rose by 4.39% to 9474.11 points, with a trading volume of 17.473 billion [1] - Over the past month, the index has increased by 16.18%, and over the last three months, it has surged by 61.71% [1] Group 2: Index Composition - The CESHKB index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd. [1] - The index is based on a reference date of December 12, 2014, with a base point of 2000.0 [1] Group 3: Top Holdings - The top ten weighted stocks in the CESHKB index include: - CanSino Biologics (13.59%) - Innovent Biologics (9.6%) - WuXi Biologics (8.91%) - 3SBio (8.66%) - BeiGene (8.33%) - WuXi AppTec (7.12%) - Kintor Pharmaceutical (4.95%) - Zai Lab (4.42%) - Genscript Biotech (3.92%) - Ascletis Pharma (3.91%) [1] Group 4: Market and Industry Overview - The CESHKB index is entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation in the healthcare sector [2]

Core Viewpoint - The Hong Kong Biotechnology Index, managed by China Securities Trading Services, has shown significant growth, with a year-to-date increase of 117.31% [1][2] Group 1: Index Performance - The Hong Kong Biotechnology Index rose by 4.33% to 9737.36 points, with a trading volume of 22.125 billion [1] - Over the past month, the index has increased by 33.88%, and over the last three months, it has risen by 64.29% [1] Group 2: Index Composition - The index is composed entirely of companies listed on the Hong Kong Stock Exchange, with a 100% allocation in the healthcare sector [2] - The top ten holdings in the index include: - CanSino Biologics (13.26%) - Innovent Biologics (9.98%) - WuXi Biologics (9.61%) - 3SBio (9.24%) - BeiGene (8.51%) - WuXi AppTec (6.21%) - Zai Lab (5.1%) - Kelun-Biotech (4.61%) - Genscript Biotech (4.07%) - Legend Biotech-B (4.05%) [1]

Group 1 - The core index, the CESHKB, experienced a decline of 1.62%, closing at 8758.46 points with a trading volume of 12.171 billion [1] - Over the past month, the CESHKB has increased by 21.79%, by 64.09% over the last three months, and has risen 98.69% year-to-date [1] - The CESHKB is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, and a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB include: CanSino Biologics (13.31%), Innovent Biologics (9.84%), 3SBio (9.12%), BeiGene (8.94%), WuXi Biologics (8.9%), WuXi AppTec (5.65%), Kintor Pharmaceutical (4.91%), Zai Lab (4.82%), Nuo Therapeutics (4.34%), and Kingstar Biotech (4.0%) [1] - The CESHKB is fully composed of stocks listed on the Hong Kong Stock Exchange, with a sector breakdown showing 59.75% in biopharmaceuticals, 23.83% in pharmaceutical and biotechnology services, 14.25% in chemical drugs, and 2.17% in medical devices [2]

Core Insights - The Chinese Securities Trading Service Hong Kong Biotechnology Index (CESHKB) has shown significant growth, with a year-to-date increase of 74.34% [1][2] - The index closed at 8009.09 points, reflecting a 2.52% increase on the day, with a trading volume of 13.721 billion yuan [1] Index Performance - The CESHKB has risen by 5.29% over the past month and 45.07% over the last three months [1] - The index is designed to reflect the overall performance of biotechnology companies listed in Hong Kong, with a base date of December 12, 2014, set at 2000.0 points [1] Index Composition - The top ten holdings of the CESHKB include: - CanSino Biologics (12.25%) - Innovent Biologics (9.96%) - 3SBio (9.44%) - WuXi Biologics (9.3%) - BeiGene (8.49%) - WuXi AppTec (5.97%) - Zai Lab (5.15%) - Kelun-Biotech (4.88%) - Legend Biotech-B (4.28%) - Genscript Biotech (4.05%) [1] Market Sector - The CESHKB is exclusively composed of companies listed on the Hong Kong Stock Exchange, with a 100% allocation to the healthcare sector [2]

Group 1 - The A-share market showed mixed results with the Chinese Securities Trading Service Hong Kong Biotechnology Index (CESHKB) declining by 2.61% to 7650.23 points, with a trading volume of 9.469 billion [1] - Over the past month, the CESHKB has increased by 15.23%, 28.86% over the last three months, and 75.31% year-to-date [1] - The CESHKB is compiled by the China Securities Index Co., Ltd. under the commission of the China Securities Trading Service Co., Ltd., aiming to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten holdings of the CESHKB include: CanSino Biologics (12.33%), Innovent Biologics (9.95%), WuXi Biologics (9.17%), 3SBio (8.66%), BeiGene (8.57%), Zai Lab (5.79%), WuXi AppTec (5.63%), Kelun-Biotech (5.28%), Ascentage Pharma-B (4.19%), and Kingstar Biotech (4.11%) [1] - The CESHKB's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation in the healthcare sector [2]

Core Viewpoint - The CESHKB index has shown significant growth, with a year-to-date increase of 64.30%, indicating a strong performance in the biotechnology sector listed in Hong Kong [1][2]. Group 1: Index Performance - The CESHKB index opened high and fluctuated, closing at 7388.22 points with a trading volume of 12.985 billion [1]. - Over the past month, the CESHKB index has risen by 14.05%, and over the last three months, it has increased by 17.80% [1]. Group 2: Index Composition - The CESHKB index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd., reflecting the overall performance of biotechnology companies listed in Hong Kong [1]. - The top ten holdings in the CESHKB index include: - CanSino Biologics (10.49%) - Innovent Biologics (9.9%) - WuXi Biologics (9.73%) - 3SBio (8.86%) - BeiGene (8.81%) - Zai Lab (5.86%) - WuXi AppTec (5.85%) - Kelun-Biotech (5.1%) - Genscript Biotech (4.42%) - Ascentage Pharma-B (4.15%) [1]. Group 3: Market and Industry Overview - The CESHKB index is entirely composed of companies listed on the Hong Kong Stock Exchange, with a 100% representation in the healthcare sector [2].

Group 1 - The core index, the CESHKB, increased by 2.7% to 7293.11 points with a trading volume of 11.568 billion [1] - The CESHKB has risen by 15.52% in the past month, 19.54% in the past three months, and 58.49% year-to-date [1] - The index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten weighted stocks in the CESHKB include: CanSino Biologics (10.91%), Innovent Biologics (9.99%), BeiGene (9.73%), WuXi Biologics (9.42%), 3SBio (8.11%), Zai Lab (6.05%), WuXi AppTec (5.56%), Kelun-Biotech (5.15%), Kingstar Bio (4.37%), and Ascentage Pharma-B (3.89%) [1] - The CESHKB is entirely composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [2] - The index's holdings are exclusively in the healthcare sector, specifically in pharmaceuticals and biotechnology, also at a 100% allocation [2]

Core Points - The Hong Kong Biotechnology Index (CESHKB) experienced a decline of 3.05%, closing at 7087.18 points with a trading volume of 11.816 billion [1] - Over the past month, the index has increased by 26.57%, by 25.92% over the last three months, and has risen 63.14% year-to-date [1] - The index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Index Composition - The top ten weighted stocks in the index include: - CanSino Biologics (10.86%) - Innovent Biologics (10.22%) - WuXi Biologics (9.54%) - BeiGene (9.36%) - 3SBio (7.95%) - Zai Lab (6.01%) - WuXi AppTec (5.63%) - Kelun-Biotech (5.20%) - Genscript Biotech (4.44%) - Ascentage Pharma-B (3.91%) [1] Market and Industry Overview - The index's holdings are entirely composed of stocks listed on the Hong Kong Stock Exchange, with a 100% representation in the pharmaceutical and healthcare sector [2]